Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options

The residual risk of patients surviving until 1 year after acute coronary syndromes (ACS) is still high, despite secondary prevention. The cornerstone of treatment of patients with ACS is dual antiplatelet therapy (DAPT) consisting of low-dose aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan Pin Yin, D. R. P. P., ten Berg, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724500/
https://www.ncbi.nlm.nih.gov/pubmed/34357557
http://dx.doi.org/10.1007/s12471-021-01604-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724500/
https://www.ncbi.nlm.nih.gov/pubmed/34357557
http://dx.doi.org/10.1007/s12471-021-01604-4

Ejemplares similares